Satellite Symposium at the
18th Meeting of the European Association for Haematopathology (EAHP)
CD30 testing: an important step towards precision medicine in haematological malignancies
3rd September 2016 18:30-19:30
Room San Francisco, Congress Center Basel
Basel, Switzerland

Dear Colleague,

You are cordially invited to the Satellite Symposium CD30 testing: an important step towards precision medicine in haematological malignancies, which will be held on Saturday 3rd September 2016. This symposium is organized by Takeda Oncology and Seattle Genetics* during the
18th Meeting of the European Association for Haematopathology (EAHP)
in Basel, Switzerland.

The aim of the symposium is to highlight the role of CD30 immunohistochemistry in the diagnosis of suspected lymphomas, including PTCL, ALCL, HL, and DLBCL. Together, we will discuss the importance and challenges of accurate lymphoma subclassification, Furthermore, we will address how CD30 pathology has evolved over the past years, and how it could continue to evolve in years to come.

During this interactive symposium, you will have the opportunity to engage in the discussions and interact with the participating experts.

We look forward to welcoming you to this stimulating and highly informative event.

Stefano Pileri, MD
European Institute of Oncology
Milan, Italy
University of Bologna
Bologna, Italy
Chair

Randy Gascoyne, MD
BC Cancer Agency
Vancouver, Canada
Chair
Chairs:

Stefano Pileri
Italy

Randy Gascoyne
Canada
This website is an
Excerpta Medica activity.
logos
Organized and funded by
logos

*Takeda Oncology is the oncology business unit brand of Takeda Pharmaceutical Company Limited.
Takeda Oncology and its logo are trademarks of Takeda Pharmaceutical Company Limited.
Seattle Genetics and its logo are trademarks of Seattle Genetics, Inc.